From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 3.08
Pain Relevance 0.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Jak2) cytosol (Jak2) signal transduction (Jak2)
histone binding (Jak2) cytoskeleton (Jak2) nucleus (Jak2)
Anatomy Link Frequency
SH2 1
bone marrow 1
portal vein 1
heart 1
Jak2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Potency 26 97.32 Very High Very High Very High
Kinase C 1 91.12 High High
abdominal pain 1 78.56 Quite High
cytokine 34 75.52 Quite High
Inflammation 32 50.00 Quite Low
fibrosis 15 22.72 Low Low
rheumatoid arthritis 22 17.36 Low Low
Arthritis 48 8.76 Low Low
aspirin 47 5.00 Very Low Very Low Very Low
cva 19 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myelodysplastic Syndromes 69 99.72 Very High Very High Very High
Myeloproliferative Disorder 27 99.68 Very High Very High Very High
Diabetes Mellitus 183 99.52 Very High Very High Very High
Cv Unclassified Under Development 13 99.26 Very High Very High Very High
Hemorrhagic Thrombocythemia 159 97.74 Very High Very High Very High
Erythrocytosis 11 97.04 Very High Very High Very High
Chronic Myeloid Leukemia 2 91.00 High High
Thrombosis Related Under Development 2 89.40 High High
Myelofibrosis 13 88.64 High High
Diabetes Complications 2 87.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
[Superior mesenteric and portal vein thrombosis in a polycythemia vera patient with JAK2 mutation].
Gene_expression (mutation) of JAK2 in portal vein associated with cv unclassified under development and myelodysplastic syndromes
1) Confidence 0.67 Published 2007 Journal Rinsho Ketsueki Section Title Doc Link 17695304 Disease Relevance 0.98 Pain Relevance 0.08
As the absence of the mutation has been repeatedly confirmed in more than 50% of ET patients, the diagnosis of ET presently remains a mixture of: 1) positive non specific arguments in favor of a Ph-negative MPD, including the JAK2 mutation and the bone marrow (BM) biopsy findings and 2) elimination of PV and IMF according to their currently used and phenotypically based definitions [12,13,20].
Gene_expression (mutation) of JAK2 in bone marrow associated with myeloproliferative disorder, hemorrhagic thrombocythemia and myelodysplastic syndromes
2) Confidence 0.55 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1781427 Disease Relevance 1.18 Pain Relevance 0
It is unclear mechanistically how CP-690,550 might spare JAK2 in cellular assays, although one explanation for reduced cellular potency could be that a cytoplasmic activator of JAK2, such as SH2-B?
Gene_expression (spare) of JAK2 in SH2 associated with potency
3) Confidence 0.54 Published 2010 Journal J Inflamm (Lond) Section Body Doc Link PMC2928212 Disease Relevance 0 Pain Relevance 0.28
These results suggest that the diabetic heart is refractory to protection by Jak2-activating ligands because of AT1 receptor-mediated upregulation of calcineurin activity.173
Gene_expression (protection) of Jak2 in heart associated with diabetes mellitus
4) Confidence 0.44 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2964943 Disease Relevance 0.92 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools